Non-Inferiority of Resolute Integrity Drug-Eluting Stent to Benchmark Xience Drug-Eluting Stent-Reference-Cited by-同舟云学术

Non-Inferiority of Resolute Integrity Drug-Eluting Stent to Benchmark Xience Drug-Eluting Stent

Published:2018-08-24 Issue:9 Volume:82 Page:2284-2291
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Nakamura Masato¹,Otsuji Satoru²,Nakagawa Yoshihisa³,Oikawa Yuji⁴,Shiode Nobuo⁵,Miyahara Masatoshi⁶,Furukawa Toshihito⁷,Nakazawa Gaku⁸,Yokoi Hiroyoshi⁹,

Affiliation:

1. Department of Cardiovascular Internal Medicine, Toho University Medical Center, Ohashi Hospital

2. Department of Cardiovascular Internal Medicine, Higashi Takarazuka Satoh Hospital

3. Department of Cardiovascular Internal Medicine, Tenri Hospital

4. Department of Cardiovascular Medicine, The Cardiovascular Institute

5. Department of Cardiovascular Internal Medicine, Tsuchiya General Hospital

6. Department of Cardiovascular Medicine, Mie Heart Center

7. Biostatistical Research Center

8. Department of Cardiovascular Internal Medicine, Tokai University Hospital

9. Department of Cardiovascular Medicine, Fukuoka Sanno Hospital

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/82/9/82_CJ-18-0011/_pdf

Reference31 articles.

1. 1. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221–231.

2. 2. Lagerqvist B, Carlsson J, Frobert O, Lindback J, Schersten F, Stenestrand U, et al. Stent thrombosis in Sweden: A report from the Swedish Coronary Angiography and Angioplasty Registry. Circ Cardiovasc Interv 2009; 2: 401–408.

3. 3. Nakazawa G, Otsuka F, Nakano M, Vorpahl M, Yazdani SK, Ladich E, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol 2011; 57: 1314–1322.

4. 4. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, et al. Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation 2007; 115: 2435–2441.

5. 5. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193–202.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ultrathin, Biodegradable-Polymer Sirolimus-Eluting Stent vs Thin, Durable-Polymer Everolimus-Eluting Stent;JACC: Cardiovascular Interventions;2022-07

2. Surgical clinical trials with non-inferiority design: a cross-sectional bibliometric analysis;Annals of Translational Medicine;2021-08

3. Ridaforolimus eluting stent for the treatment of Japanese patients with coronary disease: 1 year outcomes of the JNIR study;Cardiovascular Intervention and Therapeutics;2020-06-26